Assess Terlipressin for Hepatorenal Syndrome

January 2023

Terlipressin (Terlivaz) will be the first FDA-approved med for hepatorenal syndrome with acute kidney injury (HRS-AKI).

HRS-AKI typically occurs in patients with cirrhosis and ascites who develop splanchnic vasodilation. This causes decreased perfusion to the kidneys.

The best treatment is a liver transplant...but many patients don’t qualify for or live long enough to get a transplant.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

  • 12 issues every year — what you need to know and do, right now
  • Quick, practical reference charts and tools
  • Comprehensive CE library to meet license renewal and state requirements
  • Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
  • Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote